Patents by Inventor Emiko Hatano

Emiko Hatano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sustained-release pharmaceutical composition for treatment and prevention of eye disease
    Patent number: 10808006
    Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: October 20, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
  • SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF EYE DISEASE
    Publication number: 20190233466
    Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
    Type: Application
    Filed: February 15, 2019
    Publication date: August 1, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
  • Terpenoid derivatives
    Patent number: 10253060
    Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: April 9, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Satoshi Komoriya, Yasuhiro Nakagami, Emiko Hatano, Takashi Ohnuki, Kayoko Masuda, Mayumi Iizuka, Yasunori Ono
  • Sustained-release pharmaceutical composition for treatment and prevention of eye disease
    Patent number: 10208082
    Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: February 19, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
  • TERPENOID DERIVATIVES
    Publication number: 20180016298
    Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.
    Type: Application
    Filed: September 14, 2017
    Publication date: January 18, 2018
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Satoshi Komoriya, Yasuhiro Nakagami, Emiko Hatano, Takashi Ohnuki, Kayoko Masuda, Mayumi Iizuka, Yasunori Ono
  • Terpenoid derivatives
    Patent number: 9796752
    Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: October 24, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Satoshi Komoriya, Yasuhiro Nakagami, Emiko Hatano, Takashi Ohnuki, Kayoko Masuda, Mayumi Iizuka, Yasunori Ono
  • SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF EYE DISEASE
    Publication number: 20170260228
    Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
    Type: Application
    Filed: September 9, 2015
    Publication date: September 14, 2017
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
  • TERPENOID DERIVATIVES
    Publication number: 20160297849
    Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.
    Type: Application
    Filed: March 18, 2014
    Publication date: October 13, 2016
    Inventors: Satoshi Komoriya, Yasuhiro Nakagami, Emiko Hatano, Takashi Ohnuki, Kayoko Masuda, Mayamu Lizuka, Yasunori Ono